ARTICLE | Clinical News
AKCEA-APO(a)-LRx: Ph IIb started
April 27, 2017 9:06 PM UTC
Ionis’ Akcea Therapeutics Inc. subsidiary began a double-blind, placebo-controlled, North American Phase IIb trial to evaluate 5 dose levels of subcutaneous AKCEA-APO(a)-LRx in about 270 patients with hyperlipoproteinemia(a) and established cardiovascular disease...
BCIQ Target Profiles